YESPending Review80% confidenceGrok 4.20 (xAI)
Question
Will this trial meet its primary endpoint?
Found
Summary
Interim data from NCT06040541 (RMC-9805-001) show no DLTs, no Gr4/5 TRAEs, MTD not reached; safety primary endpoint met with manageable AEs. Sources frame encouraging antitumor activity (30% ORR PDAC, 61% NSCLC).
Sources
Web Searchascopubs.org
Preliminary safety, antitumor activity, and circulating tumor DNA changes with zoldonrasib (RMC-9805) in KRAS G12D PDAC
No DLTs or Gr 4/5 TRAEs; MTD not reached. Encouraging initial antitumor activity with 30% ORR and 80% DCR in PDAC at 1200mg; deep KRAS G12D ctDNA reductions in 86%.
Web Searchaacrjournals.org
Preliminary safety and antitumor activity of zoldonrasib (RMC-9805) in KRAS G12D NSCLC
No DLTs or Grade 4/5 TRAEs; MTD not reached. 61% ORR and 89% DCR in evaluable NSCLC patients at 1200 mg QD.